Peptide stacks · Weight and metabolism · also called Shred Stack
Tirzepatide, AOD-9604 and BPC-157 stack: what’s in it and the evidence
Checked against our library and study pagesPublished by PepVault
The Shred Stack is a blend of three compounds, tirzepatide, AOD-9604 and BPC-157, that the peptide community runs for fat loss. It isn’t one vial: the amounts the library records per dose are 2.5–10 mg of tirzepatide, 250–300 mcg of AOD-9604 and 250 mcg of BPC-157.
This page describes what the crowd runs and what a vial holds. It recommends no stack and names no seller.
What’s in the Shred Stack
| Part | Amount | What it’s there for | Evidence (library) |
|---|---|---|---|
| Tirzepatide | 2.5–10 mg | GIP/GLP-1 dual agonist — appetite suppression & glucose control | Established |
| AOD-9604 | 250–300 mcg | Studied for fat breakdown (rodents); no IGF-1 effect | Moderate |
| BPC-157 | 250 mcg | Commonly added for GI comfort (gut data from animal studies) | Emerging |
The amount per dose the library records, part by part
Tirzepatide
In the Shred Stack, tirzepatide is listed for “GIP/GLP-1 dual agonist — appetite suppression & glucose control”. The first dual GIP/GLP-1 receptor agonist: it activates two gut-hormone pathways at once, and in a head-to-head trial it produced more weight loss than semaglutide (20.2% vs 13.7% at 72 weeks).
AOD-9604
In the Shred Stack, AOD-9604 is listed for “Studied for fat breakdown (rodents); no IGF-1 effect”. A modified fragment of human growth hormone that targets fat metabolism.
BPC-157
In the Shred Stack, BPC-157 is listed for “Commonly added for GI comfort (gut data from animal studies)”. A peptide derived from a protective protein in the stomach.

Model. Individual results vary.
Has the Shred Stack been studied as a combination?
None of our 436 study pages tested the three parts of the Shred Stack together, so the Shred Stack rests on studies of its parts and on community reports.
What the library says about the evidence for the Shred Stack
Tirz nausea isn't caused by gastric damage, and no trial has tested the combination; the pattern comes from community reports.
The studies of the parts, one by one: 19 study pages on tirzepatide (18 in people), 4 study pages on AOD-9604 (0 in people) and 14 study pages on BPC-157 (2 in people).
| Part | Study pages | In people | Strongest study page |
|---|---|---|---|
| Tirzepatide | 19 | 18 | Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE (randomized trial, 2026) |
| AOD-9604 | 4 | 0 | AOD-9604 knee injections lowered cartilage damage in rabbits (animal study, 2015) |
| BPC-157 | 14 | 2 | BPC-157: 10 of 12 women reported full interstitial cystitis relief (clinical trial, 2024) |
What people commonly report on the Shred Stack
Commonly reported: easier GI tolerance on the tirzepatide ramp with BPC-157 alongside. BPC-157 alongside makes tirzepatide's nausea and GI upset easier; its gut-protective effects come from animal studies, and it hasn't been tested with GLP-1 drugs. Smoother step-ups, especially the later ones.
These are reports from people who run it, collected in the library, not results from a trial and not a promise of what any one person will notice.
Why these are combined
The library gives two reasons for combining the parts of the Shred Stack:
- Tirzepatide cuts appetite via GIP/GLP-1 while AOD-9604 adds fat breakdown (shown in rodents); in people, AOD-9604's larger trial found no weight loss, and the pair has never been tested.
- AOD-9604 is a GH fragment with no IGF-1 or blood-sugar effect in human trials, so it isn't expected to interfere with tirzepatide's metabolic signaling.
From the library’s notes on the Shred Stack
BPC-157 is commonly added for tirzepatide's GI side effects (nausea, diarrhea), and AOD-9604 for its studied effect on fat breakdown. Two GLP-1 agonists are never combined.
“Why people add BPC-157 to Tirz”, the Tirzepatide entry’s note (community report)
GI side effects during Tirz titration can be rough, and BPC-157, first studied as a stomach-protecting peptide, is added to ease them. Mechanism fit: BPC-157 is a fragment of a "body protection compound" first isolated from human gastric juice and characterized as gastroprotective in animal studies (gut mucosal integrity, reduced NSAID damage, gut-brain axis modulation).
How the parts of the Shred Stack are mixed and taken
The Shred Stack isn’t one pre-mixed vial in the library: each part has its own route and schedule, as its entry records them.
| Part | Route | How often | Our vial pages |
|---|---|---|---|
| Tirzepatide | SubQ injection | Weekly | 5 mg vial, 10 mg vial, 15 mg vial, 30 mg vial, 60 mg vial |
| AOD-9604 | SubQ injection | Daily, fasted | 5 mg vial |
| BPC-157 | SubQ injection, IM injection, Oral (less studied) | Once or twice daily | 5 mg vial, 10 mg vial |
Our vial pages work out the mix for each part’s own vial, size by size:
Compared with running the parts apart
The library’s notes on the Shred Stack don’t compare it with running its parts on their own.
Safety notes
The library holds no combination safety note on the Shred Stack, so each part’s own notes apply, on its compound page.
These are reference notes from published research and reported use, not advice for a person: discuss your own situation with your clinician.
Questions people ask
What is in the Shred Stack?
The Shred Stack is a blend of three compounds, tirzepatide, AOD-9604 and BPC-157, that the peptide community runs for fat loss. It isn’t one vial: the amounts the library records per dose are 2.5–10 mg of tirzepatide, 250–300 mcg of AOD-9604 and 250 mcg of BPC-157.
Has the Shred Stack been studied together?
Not as a combination in any of our study pages: the Shred Stack rests on studies of its parts and on community reports. From the library: Tirz nausea isn't caused by gastric damage, and no trial has tested the combination; the pattern comes from community reports.
What do people report on the Shred Stack?
Commonly reported: easier GI tolerance on the tirzepatide ramp with BPC-157 alongside. These are reports from people who run it.
Do the parts of the Shred Stack come in one vial?
No: in the library each part of the Shred Stack is its own compound with its own route and schedule (tirzepatide by SubQ injection, AOD-9604 by SubQ injection and BPC-157 by SubQ injection).
What does each part of the Shred Stack do?
The library lists tirzepatide for “GIP/GLP-1 dual agonist — appetite suppression & glucose control”, AOD-9604 for “Studied for fat breakdown (rodents); no IGF-1 effect” and BPC-157 for “Commonly added for GI comfort (gut data from animal studies)”.